Follow The Filings

LAB Standard Biotools Inc.

Industrials, filed as STANDARD BIOTOOLS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.1%
  • $48M
  • 1 exit

In 2026 Q2 Corvex Management sold out of Standard Biotools.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Andreas Halvorsen, Viking Global Investors). Not free-float ownership.

  1. Andreas Halvorsen 0.14%

Who owns LAB

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.14% Hold 58,651,170 $48M History
Corvex Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 44,340 $41K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by LAB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LAB insider trades
  • $14.4M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $503K 350,000 shares at $1.44 +0.5% to stake
    Traded Dec 2–4 Filed Dec 4, 2025
  2. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $10.1M 7,700,000 shares at $1.31 +12% to stake
    Traded Nov 24–25 Filed Nov 26, 2025
  3. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.4M 1,075,000 shares at $1.28 +1.7% to stake
    Traded Nov 18–20 Filed Nov 20, 2025
  4. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.1M 925,000 shares at $1.22 +1.5% to stake
    Traded Nov 13–17 Filed Nov 17, 2025
  5. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.4M 1,175,000 shares at $1.17 +1.9% to stake
    Traded Nov 7–12 Filed Nov 12, 2025

Also filed in the last 12 months, not counted as buying or selling: 16 share withholdings for taxes, 13 stock grants, and 2 option exercises.

Congress

No member of Congress reported trading LAB in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3
8-K 7.01,9.01
8-K 1.01,1.02,7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G/A —
8-K/A 9.01
8-K 1.01,7.01,9.01
8-K 3.01
8-K 5.02,5.07,9.01
SCHEDULE 13D —
SCHEDULE 13D/A —
8-K 1.01,3.02,5.01,5.02,7.01,9.01
8-K 8.01
8-K 5.02
8-K 5.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,7.01,9.01
DEF 14A
DEFA14A
8-K 3.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $106.34M $174.43M $85.33M
Gross profit $50.45M $84.26M $42.54M
Gross margin * 47.4% 48.3% 49.9%
Net income -$74.66M -$138.88M -$74.9M
Net margin * -70.2% -79.6% -87.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $158.22M $375.88M $454.26M
Total non-current assets * $164.85M $236.46M $113.49M
Total assets $323.07M $612.34M $567.75M
Total current liabilities $109.33M $65.89M $108.31M
Total non-current liabilities * $50.54M $74.73M $35.16M
Total equity -$148.05M $471.72M $424.29M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$43.29M -$143.45M -$74.34M
Cash from investing $20.24M $363.17M $27.41M
Cash from financing -$6.81M -$102.62M $0.57M
Net change in cash -$29.82M $116.32M -$45.52M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.